证券代码：002603 证券简称：以岭药业 公告编号：2024-011 公司2023年度已按照15%的企业所得税税率进行纳税申报及预缴，因此本 次取得高新技术企业证书不影响公司2023年度的相关财务数据。 石家庄以岭药业股份有限公司 关于通过高新技术企业重新认定的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司（以下简称"公司"） 于近日收到由河北省科 学技术厅、河北省财政厅、国家税务总局河北省税务局联合颁发的《高新技术 企业证书》（证书编号GR202313003850，发证时间为2023年12月4日，有效期 三年）。 根据相关规定，公司自获得高新技术企业认定后将连续三年享受国家关于 高新技术企业的相关优惠政策，按15%税率缴纳企业所得税。 特此公告。 石家庄以岭药业股份有限公司 董事会 2024 年 5 月 11 日 ...

Investment Rating - The investment rating for the company is to maintain attention due to its position as a leader in traditional Chinese medicine innovation [4]. Core Views - The company reported a revenue of 10.318 billion yuan in 2023, a year-over-year decrease of 17.67%, and a net profit attributable to shareholders of 1.352 billion yuan, down 42.76% year-over-year [2]. - The respiratory product line faced significant declines due to high inventory levels and a high base effect from 2022, while non-respiratory products showed steady growth [2][3]. - The company continues to invest in innovative traditional Chinese medicine research, with a total R&D expenditure of 935 million yuan in 2023, representing 9.06% of revenue [3]. Financial Summary - Revenue projections for 2024-2026 are 11.386 billion yuan, 12.541 billion yuan, and 13.717 billion yuan, with corresponding growth rates of 10.35%, 10.14%, and 9.38% [4]. - Net profit forecasts for the same period are 1.532 billion yuan, 1.759 billion yuan, and 1.990 billion yuan, with growth rates of 13.27%, 14.83%, and 13.10% [4]. - The company’s earnings per share (EPS) are projected to be 0.92 yuan, 1.05 yuan, and 1.19 yuan, with price-to-earnings (P/E) ratios of 21, 18, and 16 respectively [4][5].

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's performance is under pressure in the short term due to high base effects, but it aims for steady development in 2024. The revenue for 2023 was 10.318 billion, a year-on-year decline of 17.67%, and the net profit attributable to the parent company was 1.352 billion, down 42.76% [1][2] - The company plans to leverage its "Seventh Five-Year" strategic plan to enhance operational management, improve R&D efficiency, and optimize its marketing system to achieve stable growth [1][2] - The company has maintained stable growth in sales of other patented products, with cardiovascular products generating revenue of 4.709 billion in 2023, up 12.71%, while respiratory products saw a significant decline of 51.90% [1][2] Financial Summary - The company forecasts revenues of 11.683 billion, 13.523 billion, and 15.703 billion for 2024, 2025, and 2026 respectively, with net profits of 1.948 billion, 2.245 billion, and 2.586 billion for the same years [2][3] - The gross margin is expected to be 57.8% in 2024, slightly down from 57.3% in 2023, while the net asset return (ROE) is projected to be 14.6% [2][3] - The company reported a diluted EPS of 1.17 in 2024, with a P/E ratio of 16.34 [2][3] R&D and Innovation - The company is actively advancing new drug development in its core areas of traditional Chinese medicine and chemical drugs, with 22 new national invention patents and 7 international invention patents granted in 2023 [1][2] - The focus for 2024 includes enhancing core technologies and innovation capabilities, particularly in the development of innovative traditional Chinese medicine and chemical drugs targeting new therapeutic areas [1][2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][3] Core Views - The company's short-term operating performance is under pressure, but its innovative attributes support long-term development [3] - The company achieved a revenue of 10.318 billion yuan in 2023, a year-on-year decrease of 17.67%, and a net profit attributable to shareholders of 1.352 billion yuan, down 42.76% [3] - The company is expected to see a gradual recovery in net profit, with projections of 1.450 billion yuan in 2024, 1.563 billion yuan in 2025, and 1.730 billion yuan in 2026 [3] Financial Performance Summary - In Q1 2024, the company reported a revenue of 2.523 billion yuan, a decrease of 35.89%, and a net profit of 304 million yuan, down 74.73% [3] - The gross margin for 2023 was 57.28%, a decline of 6.49 percentage points, while the net margin was 13.03%, down 5.78 percentage points [3] - The company’s R&D expense ratio was 8.27% in 2023, reflecting its commitment to innovation [3] Product Performance - Cardiovascular products generated revenue of 4.709 billion yuan in 2023, an increase of 12.71%, while respiratory products saw a significant decline in revenue by 51.90% to 3.305 billion yuan [4] - The gross margin for cardiovascular products was 58.36%, down 6.53 percentage points, while respiratory products maintained a gross margin of 69.19% [4] Innovation and Development - The company is advancing its innovative traditional Chinese medicine (TCM) products, focusing on key disease areas such as cardiovascular, respiratory, and endocrine disorders [5] - The company has successfully launched a new TCM product for diabetic retinopathy and has several products in various stages of clinical trials [5] - The company’s strategy includes a dual approach of developing generic drugs and innovative patented drugs, with a strong pipeline for future growth [5]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company experienced significant pressure on its performance in 2023 and Q1 2024, with revenues and profits declining sharply. However, there is an expectation for gradual improvement in Q2 2024 [2] - The company is focusing on innovative research and development in traditional Chinese medicine, particularly in cardiovascular and respiratory health products, which positions it to benefit from policy incentives in the sector [2][4] Summary by Sections Financial Performance - In 2023, the company reported revenues of 10.318 billion yuan, a decrease of 18% year-on-year, with net profit down 43% to 1.352 billion yuan. The cash flow from operations fell by 96% to 155 million yuan [2] - For Q1 2024, revenues were 2.523 billion yuan, down 36% year-on-year, with net profit declining 75% to 304 million yuan [2] - The company proposed a cash dividend of 3.0 yuan per 10 shares, resulting in a payout ratio of 37% [2] Product Performance - Revenue breakdown for 2023 shows cardiovascular products at 4.709 billion yuan (+13%), respiratory products at 3.305 billion yuan (-52%), and other proprietary products at 435 million yuan (+14%) [2] - The respiratory product segment faced significant challenges, while cardiovascular and other proprietary products showed stable growth [2] Research and Development - The company invested 935 million yuan in R&D in 2023, accounting for 9.06% of revenue, an increase of 1.91 percentage points year-on-year [2] - Key R&D achievements include the approval of Tongluomingmu capsules for diabetic retinopathy and the completion of phase III clinical trials for several other products [2] Profit Forecast and Valuation - The profit forecasts for 2024 and 2025 have been revised down to 1.500 billion yuan and 1.931 billion yuan, respectively, reflecting a 49% and 45% reduction from previous estimates. A new forecast for 2026 is set at 2.380 billion yuan [2] - The current price corresponds to a P/E ratio of 22, 17, and 14 for 2024, 2025, and 2026, respectively [2]

石家庄以岭药业股份有限公司 2023 年度独立董事述职报告 （陈刚） 本人作为石家庄以岭药业股份有限公司（以下简称"公司"或"以岭药业"） 的独立董事，严格按照《公司法》《上市公司治理准则》《上市公司自律监管指引 第 1 号——主板上市公司规范运作》等法律法规以及《公司章程》、公司《独立 董事制度》的规定，本着客观、公正、独立的原则，勤勉尽责，积极发挥独立董 事作用，维护公司整体利益和全体股东尤其是中小股东的合法权益。 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 1 号—主板上市公司规范运作》等相关规定，本人作为公司独立董事，对 自身独立性情况进行了自查。2023 年度，本人未在公司担任除独立董事以外的 任何职务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间 不存在利害关系或其他可能妨碍其进行独立客观判断的关系，本人任职符合 《上市公司独立董事管理办法》等规定的独立性要求，不存在影响独立性的情 形。 二、2023 年度履职概况 本人积极参加公司召开的董事会和股东大会，认真审阅会议相关材料，积极 参与各项议案的讨论并提出合理建议，为董事会的正确、科学决策发挥积极作用。 ...

目录 CONTENTS | 04 | 报告说明 | 16 | 责任聚焦 一 | 78 | 展望 2024 | | --- | --- | --- | --- | --- | --- | | 06 | 高管致辞 | | 药香飘满致富路，乡村振兴有"良方" | 80 | 附录 | | 08 | 关于以岭 | 20 | 责任聚焦 二 | | | | | | | 点亮"红色引擎"，凝聚党建合力 | | | | "以"药为引 | | | --- | --- | | "岭"航健康明天 | | | 50 | 坚守传承创新 | | 54 | 加强品质管控 | | 56 | 升级服务体验 | "以"治为基 "岭"承经营风采 完善公司治理 强化责任管理 守牢合规底线 24 27 30 22 58 34 68 | "以"绿为卷 "岭"会自然之美 | | | --- | --- | | 36 | 强化环境管理 | | 40 | 节能减排降耗 | | 46 | 绿色低碳运营 | | "以"心为始 "岭"路和谐社会 | | | --- | --- | | 70 | 携手伙伴共赢 | | 74 | 共享健康生活 | | 75 | 温情回馈 ...

关于对石家庄以岭药业股份有限公司 勤信专字【2024】第 0729 号 | 内 容 | 页 | 次 | | --- | --- | --- | | 控股股东及其他关联方占用 | 1-2 | | | 资金情况的专项说明 | | | | 附表 | 3 | | | | | 中勤万信会计师事务所 地址：北京西直门外大街 112 号阳光大厦 10 层 电话：（86-10）68360123 传真：（86-10）68360123-3000 邮编：100044 非经营性资金占用及其他关联资金往来情况 关于石家庄以岭药业股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项说明 的专项说明 勤信专字【2024】第 0729 号 石家庄以岭药业股份有限公司全体股东： 二○二四年四月二十六日 中国注册会计师：常素兰 我们接受委托，依据《中国注册会计师执业准则》审计了石家庄以岭药业股 份有限公司（以下简称以岭药业公司）的财务报表，包括 2023 年 12 月 31 日的 合并及母公司资产负债表，2023 年度的合并及母公司利润表、合并及母公司现 金流量表、合并及母公司股东权益变动表以及财务报表附注，并于 2024 年 4 月 ...

石家庄以岭药业股份有限公司董事会 关于独立董事独立性自查情况的专项意见 经核查独立董事刘骁悍先生、陈刚先生的任职经历及其签署的独立性自查 文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股 东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨 碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号— —主板上市公司规范运作》及公司《独立董事制度》中对独立董事独立性的相 关要求。 石家庄以岭药业股份有限公司 董事会 2024 年 4 月 27 日 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 等要求，就石家庄以岭药业股份有限公司（以下简称"公司"）第八届董事会在 任独立董事刘骁悍先生、陈刚先生的独立性情况进行评估并出具如下专项意 见： ...

证券代码：002603 证券简称：以岭药业 公告编号：2024-007 石家庄以岭药业股份有限公司 关于预计 2024 年度日常关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、 日常关联交易基本情况 （一）日常关联交易概述 石家庄以岭药业股份有限公司（以下简称"公司"或"本公司"）及子公司因经 营需要，与公司控股股东以岭医药科技有限公司（以下简称"以岭医药科技"）及 其子公司以岭络病健康医疗管理有限公司（以下简称"以岭络病"）、河北以岭国 医堂健康医疗管理有限公司（含分公司）（以下简称"以岭国医堂"）、以岭德衡 医院（衡水）有限公司（以下简称"以岭德衡医院"）、石家庄以岭健康体检中心 有限公司（以下简称"以岭体检中心"）、以岭互联网医院（河北）有限公司（以 下简称"以岭互联网医院"）以及河北以岭医院之间存在日常经营性关联交易。 根据公司（含子公司）与关联方 2023 年度交易的实际情况并合理预计，公 司预计 2024 年与关联方日常关联交易总额不超过人民币 6,262 万元。 根据《深圳证券交易所股票上市规则》的规定及《公司章程》等有关规定 ...